Related references
Note: Only part of the references are listed.Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
C. E. Collins et al.
LUPUS SCIENCE & MEDICINE (2016)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
M. Mosca et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
A population-based assessment of systemic lupus erythematosus incidence and prevalenceresults and implications of using administrative data for epidemiological studies
S. Bernatsky et al.
RHEUMATOLOGY (2007)
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
EM Ginzler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
KP Baker et al.
ARTHRITIS AND RHEUMATISM (2003)
Immunosuppressive therapy in lupus nephritis -: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide
FA Houssiau et al.
ARTHRITIS AND RHEUMATISM (2002)
Management of lupus erythematosus: recent insights
DJ Wallace
CURRENT OPINION IN RHEUMATOLOGY (2002)
Mortality and causes of death in systemic lupus erythematosus
J Trager et al.
CURRENT OPINION IN RHEUMATOLOGY (2001)
Systemic lupus erythematosus
G Ruiz-Irastorza et al.
LANCET (2001)
Share Paper
